These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 18485142)

  • 1. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
    Budhiraja S; Singh J
    Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of protein kinase C activation and the vascular complications of diabetes.
    Das Evcimen N; King GL
    Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of protein kinase C in the pathophysiology of diabetic retinopathy].
    Lang GE; Kampmeier J
    Klin Monbl Augenheilkd; 2002 Nov; 219(11):769-76. PubMed ID: 12494366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of PKC in the pathogenesis of diabetic vascular complications].
    Inoguchi T; Umeda F
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():67-72. PubMed ID: 12430209
    [No Abstract]   [Full Text] [Related]  

  • 7. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanism of diabetic nephropathy].
    Ohshiro Y; Takasu N
    Nihon Rinsho; 2006 May; 64(5):997-1003. PubMed ID: 16689387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of diabetic retinopathy.
    Lang GE
    Ophthalmologica; 2007; 221(2):112-7. PubMed ID: 17380065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
    Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
    Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific medical intervention for diabetic retinopathy.
    Ng JS
    Med Hypotheses; 2009 Aug; 73(2):158-60. PubMed ID: 19380207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
    Danis RP; Sheetz MJ
    Expert Opin Pharmacother; 2009 Dec; 10(17):2913-25. PubMed ID: 19929710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Potential therapeutic targets for diabetic nephropathy].
    Makino Y; Haneda M
    Nihon Rinsho; 2009 Aug; 67(8):1627-35. PubMed ID: 19768953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C activation and its role in kidney disease.
    Li J; Gobe G
    Nephrology (Carlton); 2006 Oct; 11(5):428-34. PubMed ID: 17014557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C-beta inhibition: a promise not yet fulfilled.
    Bakris GL
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):619-20. PubMed ID: 17699472
    [No Abstract]   [Full Text] [Related]  

  • 17. PKD at the crossroads of DAG and PKC signaling.
    Wang QJ
    Trends Pharmacol Sci; 2006 Jun; 27(6):317-23. PubMed ID: 16678913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of protein kinase C activation in diabetic nephropathy.
    Noh H; King GL
    Kidney Int Suppl; 2007 Aug; (106):S49-53. PubMed ID: 17653211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy.
    Aiello LP; Cahill MT; Cavallerano JD
    Eye (Lond); 2004 Feb; 18(2):117-25. PubMed ID: 14762400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase C-beta inhibition for diabetic kidney disease.
    Tuttle KR
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.